

## NFC IMMUNOASSAYS


### EXAMPLE: URINE BASED PROSTATE CANCER TEST (PCADM-1)

#### GT-401

#### SUMMARY

GENTAG and MacroArray Technologies, LLC have joined forces to develop a new, disposable, urine-based immunoassay diagnostic test for prostate cancer. This new test is envisioned to supplant, and potentially replace, the PSA blood test currently in use worldwide. It is based on MacroArray Technologies, LLC proprietary PCADM-1 biomarker and GENTAG's wireless network sensor platform technology.

The advantages of the test are that it is non-invasive, easily administered, safe and extremely cost effective for the diagnosis of prostate cancer. The availability of a simple, yet reliable, urine-based test (similar to the pregnancy test) will facilitate periodic testing of the overall medical condition of men over 50, and more specifically, the absence or presence of prostate cancer. Results can be communicated directly to a physician via cell phone or PC. The market for a consumer-based prostate cancer test is estimated at \$1.6B.



#### COMMERCIALIZATION

The PCADM-1 biomarker has been demonstrated to be a highly effective biomarker for prostate cancer in blind clinical tests. Both companies are interested in identifying a corporate partner to assist in the commercialization of this device. FDA approval will be required prior to commercialization.

For more information contact GENTAG at:

[info@gentag.com](mailto:info@gentag.com)